Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ayman M. Metwally has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 December 2016
      • Vol. 46  (6) , 592-600

    FLT3 Internal Tandem Duplication Mutation, cMPL and CD34 Expressions Predict Low Survival in Acute Myeloid Leukemia Patients.

    by Eman K Ebrahim, Magda Assem, Ahmed I Amin, Mahmoud M Kamel, Yomna M El Meligui, Ayman M Metwally

    To detect FMS-like tyrosine kinase-3 internal tandem duplicate (FLT3 ITD) mutation, Myeloproliferative leukemia virus oncogene (cMPL) and Ephrin A 4 receptor (EphA4) expressions in Acute myeloid leukemia (AML) and their correlation to patient's clinicopathological characteristics and survival. RNA was extracted from blood samples of 58 AML patients (39 adults and 19 children) and 20 age and sex matched controls. FLT3 ITD mutation, cMPL and EphA4 expression was studied using RT-PCR and correlated to the clinical and survival data of the patients. FLT3 ITD mutation, cMPL and EphA4 expression was positive in 35.9%, 76.9% and 56.4% of adult AML patients respectively and in 15.8%, 47.4% and 36.8% of pediatric AML patients respectively. 76.9% of adult and 89.5% of pediatric patients expressed CD33. 64.1 % of adults and 42.1% of children expressed CD34. CD34 expression was significantly associated with both FLT3 ITD mutation and cMPL expression. CD34, FLT3 and cMPL negative cases have significantly higher overall survival than positive cases. CD34 expression is significantly associated with both FLT3 ITD mutation and cMPL expression which could be used as a marker for low survival. Normal FLT3 and negative expression of CD34 and cMPL may predict a longer overall survival. Further studies are needed to investigate the mechanism that may correlate CD34 to both markers.


  • Open Access

    Role of cyclins A and E in endometrial carcinogenesis in breast cancer patients under tamoxifen treatment

    by Ayman M. Metwally, Lobna A. Refaat, HebatAllah Shaaban, Somaia Megm, Mohamed Emara, Amany A. Tohamy, Eman Abou Sinna, Hussein Khaled

    PurposeThe objective of our study was to determine the relevance of cyclins A and E overexpression in endometrial carcinogenesis in hormone receptor-positive breast cancer patients under tamoxifen therapy.Experimental designWe assessed expression of cyclins A and E in Endometrial cytology samples collected from 36 ER and PR positive breast cancer patients; under tamoxifen treatment by using the Tao-brush non-invasive brushing cytology technique. Cyclins were detected in the collected samples by means of immuno-cytochemistry.The patients included in this study are a cohort of 36 breast cancer patients who were operated upon at the National Cancer Institute – Cairo University in the period from February 2006 to May 2008 and received tamoxifen (TAM) as part of their adjuvant treatment.ResultsCyclins A and E were expressed in 17 and 15 of the 36 collected endometrial cytology samples (47.2% and 41.6% respectively).Expression of cyclins A and E was highly correlated to Tamoxifen exposure duration (32 and 43months respectively) p<0.001. Tamoxifen median exposure duration was shortened to 21months in cases showing positivity for either markers, while in cases showing positivity for both cyclins, the median exposure duration was longer (44.5months) (p<0.001). Neither cyclin A nor E was detected before median tamoxifen exposure duration of 11months. Endometrial carcinoma cases had the longest Tamoxifen exposure duration (60months).ConclusionCyclins A and E expression is involved in the carcinogenesis of endometrium in women with breast cancer and under tamoxifen-treatment. Follow up of the patients using these 2 markers is highly recommended starting from the 12th month